The turnover rates of low density lipoprotein-apolipoprotein (apoLDL) were determined in eight men with coronary heart disease (CHD) and seven men matched for age, weight, and plasma lipid levels who were used for controls. The CHD patients were normocholesterolemic (plasma cholesterol = 204 ± 8 mg/dl SEM) as were the control subjects (227 ±15 mg/dl). The concentrations of plasma LDL cholesterol and apoLDL were similar for the two groups. In contrast, the synthetic rates of apoLDL were higher in the CHD patients (20.0 ± 1.8 mg/kg/day) than in the controls (12.9 ± 1.1 mg/kg/day) (p < 0.01). The ratios of protein-to-cholesterol in LDL averaged 19% higher in the CHD patients. These patients with CHD maintained normal LDL levels despite an over-production of apoLDL because of an increased capacity for LDL removal; their fractional catabolic rates of apoLDL averaged 43% higher than those of the controls. These findings indicate that some patients with CHD have abnormalities in the turnover of apoLDL, even with normal concentrations of LDL; these abnormalities may contribute to accelerated atherosclerosis. (Arteriosclerosis 3:40-46, January/February 1983) E levated levels of total plasma cholesterol and the major cholesterol-carrying lipoprotein, low density lipoprotein (LDL), are associated with increased risk for coronary heart disease (CHD).
The turnover rates of low density lipoprotein-apolipoprotein (apoLDL) were determined in eight men with coronary heart disease (CHD) and seven men matched for age, weight, and plasma lipid levels who were used for controls. The CHD patients were normocholesterolemic (plasma cholesterol = 204 ± 8 mg/dl SEM) as were the control subjects (227 ±15 mg/dl). The concentrations of plasma LDL cholesterol and apoLDL were similar for the two groups. In contrast, the synthetic rates of apoLDL were higher in the CHD patients (20.0 ± 1.8 mg/kg/day) than in the controls (12.9 ± 1.1 mg/kg/day) (p < 0.01). The ratios of protein-to-cholesterol in LDL averaged 19% higher in the CHD patients. These patients with CHD maintained normal LDL levels despite an over-production of apoLDL because of an increased capacity for LDL removal; their fractional catabolic rates of apoLDL averaged 43% higher than those of the controls. These findings indicate that some patients with CHD have abnormalities in the turnover of apoLDL, even with normal concentrations of LDL; these abnormalities may contribute to accelerated atherosclerosis. (Arteriosclerosis 3:40-46, January/February 1983) E levated levels of total plasma cholesterol and the major cholesterol-carrying lipoprotein, low density lipoprotein (LDL), are associated with increased risk for coronary heart disease (CHD). 12 However, concentrations of plasma total and LDL cholesterol overlap considerably among people with and without premature CHD. Recently, high levels of LDL apolipoprotein B (apo B) have been reported to separate patients with CHD from unaffected people better than do total cholesterol, triglycerides (TG), or LDL cholesterol. 3 In this same report, patients were described who had advanced atherosclerosis, elevated LDL apo B, but normal LDL cholesterol. Thus, abnormalities in metabolism of LDL apo B, which may not be reflected in LDL cholesterol concentrations, could contribute to atherosclerosis. To examine this possi-bility further, we undertook this study to determine the production and removal of LDL protein (apoLDL, which is over 90% apo B) in patients with CHD and in control patients matched for age, sex, and plasma lipid concentrations.
Methods Patients
Eight men with well-documented CHD and seven healthy men (controls) were studied (table 1) . At the time of the study, the CHD patients were 60 ± 3 years old (SEM) (an age range of 49 to 71 years) and their ages at the clinical onset of CHD averaged 51 ± 3 years (from 43 to 66 years). Their mean body weight was 74 ± 2 kg (mean ideal weight = 108 ± 3%). In six patients, coronary artery bypass grafting was done an average of 6 years after the onset of CHD. The two patients without grafts had had previous myocardial infarctions proven by electrocardiograms and enzyme changes. Many patients had bruits over carotid and femoral arteries, but none had clinical heart failure. Also, none had xanthomata, xanthelasma, fasting or 2-hour postprandial hyperglycemia. Four patients (Nos. 1, 2, 3, and 4) were taking propranolol for hypertension; two (Nos. 2 and 3) were on diuretics. All patients were normotensive at the time of the study. None were on llpid-lowering drugs. Most patients were smokers before their first myocardial infarction but had stopped or greatly reduced smoking after their attacks. The patients' dietary habits before admission were reviewed carefully. One patient (No. 2) claimed that he attempted to decrease his cholesterol intake after heart surgery. None of the others was on a special diet; several had been told that dietary change was not necessary because of normal plasma cholesterol. The lipid concentrations determined on their home diets revealed normal plasma cholesterol and TG (table 1) ; all values were below the 95th percentile for the patients' age and sex by the criteria of the Lipid Research Clinics Program Prevalence Study. 4 ' 5 The seven control subjects had no history of CHD. Their ages averaged 60 ± 2 years (from 54 to 68 years) and their weights were 76 ± 5 kg (109 ± 5% ideal weight). Some subjects were smokers, but none had hypertension, diabetes mellitus, or hepatic or renal disease. None were on digitalis, diuretics, or beta-adrenergic blocking agents. Their electrocardiograms were normal, as were their cardiovascular systems by physical examination. None were or had been on lipid-lowering diets or drugs. Their plasma lipid levels at home, with perhaps one exception (No. 5), were below the 95th percentile for their age and sex 45 (table 1) .
Experimental Design
All patients underwent measurement of turnover of LDL-protein (apoLDL) at the Special Diagnostic and Treatment Unit, Veterans Administration Medical Center, San Diego. The length of their hospitalization was 4 to 5 weeks. A uniform isocaloric diet of mixed solid food and liquid formula was served throughout the study; it contained 40% of calories as fat, mostly in the form of lard, 45% as carbohydrate, and 15% as protein. The details of this diet have been described previously. 8 The ratio of polyunsaturated-to-saturated fats was ~ 0.27, and the cholesterol intake was about 100 mg/day. Vitamin and mineral supplements were given daily. The patients received 0.5-0.9 g/day of potassium iodide orally in divided doses for 5 days before and throughout each study.
Methodology
The measurements of apoLDL turnover were performed as previously described. 7 I was removed by dialysis and the labeled LDL was diluted with 5% human serum albumin and sterilized by passage through a 0.22 nm Millipore filter. The labeled LDL was injected intravenously; it contained 50-70 fid of radioactivity and 2-10 mg of protein. Blood samples were collected at 5,10,15,20,30 and 60 minutes and at 3, 6,9,12,24,36 and 48 hours and daily (after fasting) for 14 to 21 days thereafter. Determinations of radioactivity and concentrations of total cholesterol and triglyceride were made on each plasma sample. Lipoprotein-lipid quantification was done biweekly throughout the study. Plasma radioactivity was measured in a gamma counter. The fractional catabolic rate (FCR) and synthesis rate for apoLDL were determined as previously described. 78 Briefly, two exponential components of the die-away curve of plasma radioactivity were fitted to the 2-pool Matthews model;
11 the data were used to calculate FCR for plasma apoLDL. The synthetic rate for apoLDL was calculated as follows: apoLDL synthesis = (plasma apoLDL concentration) x (plasma volume) x FCR. Plasma volume was calculated by the isotope-dilution technique from the known injected dose and the intercept of the calculated 2-exponential curve. The concentration of apoLDL was calculated from the mean of the 4 to 6 measured ratios of protein-tocholesterol and the 4 to 6 measured values for LDL cholesterol in each patient's LDL. These measurements were done biweekly throughout the study. Total plasma cholesterol and TG were determined on a Technicon Auto-analyzer (Model II, Technicon Instruments Corporation, Tarrytown, New York.) 12 - 13 The concentrations of cholesterol and TG in very low density lipoproteins (VLDL), low density lipoproteins, and high density lipoproteins (HDL) were estimated as described in the Lipid Research Clinics Manual at Laboratory Operations.
14 The protein-to-cholesterol ratio in LDL was measured after ultracentrifugation, but plasma apoLDL was calculated from that ratio and from the LDL-cholest6rol separately. The latter determination did not involve ultracentrifugation. The correction assumed that ultracentrifugal losses of protein and cholesterol in LDL were similar. The protein content of LDL was estimated by a modified method of Lowry et al., 15 as described by Sata et al.
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Results
Lipid concentrations in the total plasma and llpoprotein fractions are compared for CHD patients and controls in table 2. No differences were noted for the plasma lipids between the home diet (table 1) and the metabolic diet (table 2). For CHD patients on the metabolic diet, all lipid and lipoprotein values were below the 95th percentile for their sex and age group. 45 The same was true for the controls except one subject (No. 5) whose total and LDL cholesterol were near the 95th percentile. The CHD and control groups showed no differences in plasma total cholesterol (204 ± 8 (SEM) vs 227 + 15 mg/dl, respectively), LDL cholesterol (135 ± 6vs 148 ± 12 mg/dl), or total TG (141 ± 11 vs 159 ± 21 mg/dl). However, CHD patients frequently had lower HDL cholesterol than did the controls (44 ± 2 vs 54 ± 5 mg/dl, respectively, p < 0.08). Table 3 presents the kinetic parameters for 12S IapoLDL in both groups. LDL cholesterol levels in CHD patients (135 ± 6 SEM mg/dl) were similar to 'Fraction of Intravascular apoLDL pool metabolized each day, calculated either from the plasma die-away curve (I) or from UP ratio (II).
tPercentage of total body apoLDL contained in the intravascular space. $CHD significantly higher than controls by Student's f test (p < 0.02 or less). IW = ideal weight.
control subjects (148 ± 12 mg/dl). Plasma apoLDL concentrations in CHD patients (109 ± 3 mg/dl) were slightly but not significantly higher than in the controls (100 ± 9 mg/dl); also, patients with CHD had higher LDL protein-to-cholesterol ratios (0.81 ± 0.02) than did controls (0.68 ± 0.04) (p < 0.02). Synthetic rates of apoLDL were higher in CHD patients (20.0 ± 1.8 mg/kg/day) than in controls (12.9 ± 1.1 mg/kg/day) (p < 0.01). Finally, the FCRs for apoLDL in CHD patients (0.427 ± 0.032 day" 1 ) were elevated over those in the controls (0.298 ± 0.020 day 1 ) (p < 0.005); this translates into a shorter residence time for apoLDL in CHD patients (2.4 ± 0.2 days) vs 3.4 ± 0.2 days for the controls.
Discussion
The risk for CHD is increased in patients with elevated plasma cholesterol and LDL cholesterol. 12 Many patients with CHD, however, have increases in neither, suggesting that factors unrelated to cholesterol levels could be mainly responsible for their coronary atherosclerosis. Still, abnormalities in lipoprotein metabolism besides elevated LDL or total plasma cholesterol have been implicated In atherogenesis. One of these is hypertriglyceridemia; Normocholesterolemic patients with reduced HDL also have heightened risk for CHD. 2627 Recently Sniderman et al. 3 have postulated yet another lipoprotein abnormality predisposing to CHD; they observed a group of patients with CHD who had increased LDL apo B and normal LDL cholesterol. A disproportionate increase of apo B in LDL thus could be another independent risk factor.
The current results may have uncovered yet another defect in apo B metabolism in patients with accelerated atherosclerosis. Our patients with CHD frequently had an overproduction of apoLDL even when the LDL cholesterol was relatively normal. Although LDL cholesterol on the average was the same for both control subjects and CHD patients, the mean synthetic rates of apoLDL in CHD patients were 55% greater than in the controls (p < 0.01).
Our study patients with CHD were intentionally selected for normal levels of plasma total cholesterol and TG. All values for lipids and lipoproteins were below the 95th percentile for their age and sex according to the criteria of the Upid Research Clinics Program Prevalence Study. 45 The study patients were compared to subjects with similar levels of lipids and lipoproteins who did not show clinical evidence of CHD or other atherosclerotic diseases. Although the control patients did not have manifest CHD, they probably had some degree of coronary atherosclerosis. The CHD patients, nonetheless, almost certainly had more advanced atherosclerosis. They generally had clinical manifestations of CHD several years younger than the ages of the control patients at the time of study. Also, significant differences in apoLDL turnover were found between the two groups, and these differences might have been even larger had the control group included subjects with an angiographically proven absence of coronary artery disease.
We can consider some possible reasons for the increased turnover of apoLDL in CHD patients. We must ask first whether a higher turnover was the result and not the cause of CHD. If it was secondary to coronary disease, dietary change after myocardial infarction would seem the most likely explanation. A careful review of dietary histories, however, uncovered only one patient who had consciously attempted to alter his eating habits. None had undergone significant weight gain after the onset of clinical disease; their percentage of ideal body weight was no greater than that of the controls, and no correlation was noted between their percentage of ideal weight and apoLDL synthesis. It thus seems most unlikely that the increased turnover of apoLDL in our CHD patients was a peculiar response to the metabolic diet. Recent reports indicate that synthesis rates of apoLDL generally are unaffected by changes in either intakes of cholesterol 28 or by P/S ratios of dietary fats. 29 Therefore, an increased production of apoLDL in patients with CHD, compared to controls, probably was not due to differences in diet or caloric state.
Our CHD patients not only had high synthetic rates of apoLDL, they also had enhanced FCR of LDL. The reason for the elevated clearance of LDL cannot be explained by the current data. Theoretically, a high FCR could reflect greater removal by either receptor or nonreceptor pathways by LDL catabolism, but the two pathways cannot be distinguished using a single isotopic tracer for LDL.
The current CHD patients were selected because of their relatively normal levels of total cholesterol. Many patients with CHD have elevated total or LDL cholesterol. Most of the latter probably have a high production of apoLDL with a normal FCR. This postulation is based on our report 8 that concentrations of plasma LDL correlate closely with their production rates over a wide range of LDL levels. Differences in synthesis, and not FCR, of LDL thus appear to be the major factor regulating LDL concentrations. The CHD patients in our study seem to be an exception to this generalization. Despite increased LDL synthesis, they were protected from hypercholesterolemia by enhanced clearance. They nonetheless had increased LDL flux through plasma, suggesting that excessive production of LDL may enhance atherogenesis independent of LDL concentrations.
If overproduction of apoLDL with normocholesterolemia can accelerate atherosclerosis, we might inquire into the mechanisms. One possibility is that the lipid levels measured on our CHD patients were not indicative of their previous values. However, only one patient had made any attempt to lower his cholesterol through diet, and for both control and CHD patients, the lipid levels on their unrestricted diets at home were essentially the same as those during the study. Our findings, however, do not rule out the possibility that overproduction of apoLDL is associated with transitory periods of hypercholesterolemia and hence increased risk for CHD.
This latter possibility raises the question whether some of our patients had a normolipidemic variant of familial combined hyperiipidemia. This latter disorder is manifested by elevated cholesterol, TG, or both, and by multiple lipoprotein phenotypes in the same family. 303233 Those with elevated LDL almost certainly have excessive synthesis of LDL apo B as well, 31 and overproduction of apo B may be the fundamental metabolic defect in this disorder. Familial combined hyperiipidemia confers an increased risk of CHD regardless of lipoprotein phenotype; 20 21 this greater risk is present even in those with high VLDL and normal LDL. 24 An intriguing possibility is that some patients with this disorder are normolipidemic and yet are still at increased risk.
Another mechanism by which abnormally high synthesis of apo B might raise the risk for CHD is by the formation of unusually "atherogenic" lipoproteins. This hypothesis is attractive because of the report by Sniderman et al. 3 that some patients with CHD have an LDL fraction disproportionately enriched with apo B. Our CHD patients did not have significantly higher concentrations of apoLDL than did the controls, but they did have a significantly higher ratio of protein-to-cholesterol in LDL. Their "apo B-rich" LDL thus could have increased atherogenic potential.
An elevated LDL protein-to-cholesterol ratio could be a reflection of an overproduction of LDL apo B; i.e., high turnover rates of LDL may raise the ratio. The longer LDL remains in the plasma, the more cholesterol ester it should acquire either through reaction with lecithin cholesterol acyltransferase (LCAT) 34 or by transfer from HDL.
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" 37 If LDL is removed rapidly from the circulation, it should acquire less than normal amounts of cholesterol ester for a given amount of apo B. Indeed, by combining all the subjects of the present study, we found a positive correlation between the FCR of apoLDL and the protein-to-cholesterol ratio in LDL (r = 0.51, p < 0.05). Nonetheless, other mechanisms for a high ratio are possible. One possibility could be direct (VLDLindependent) synthesis of LDL; another is that the ratio is dependent upon the efficiency of the VLDL delipidation system so that more cholesterol is removed during conversion of VLDL to LDL. Regardless of the mechanism, LDL that is relatively rich in apo B and poor in cholesterol may be unusually atherogenic.
Finally, we can consider two other mechanisms for accelerated atherosclerosis with overproduction of LDL apo B. First, an increased influx of apo B may "saturate" the normal, receptor-mediated clearance o', LDL; if so, a greater fraction of LDL would be removed through the nonreceptor pathway. If this were to occur within the arterial wall, foam cell formation could be enhanced. 3839 Second, an increased delivery of cholesterol to peripheral tissues secondary to a high turnover of LDL may overload the reverse cholesterol transport. The precise means' by which cholesterol is removed from peripheral tissues is not known, but it is conceivable that a generalized overloading of the mechanism of reverse cholesterol transport could reduce the clearance of cholesterol from the arterial wall.
This and other reports 3830 " 32 suggest a connection between a primary overproduction of apo B and an enhanced risk for CHD. Excessive production of apo B can be clinically manifested in several different forms. If overproduction of apo B and VLDL-TG occur simultaneously, patients will have a predominant hypertriglyceridemia. 33 If TG synthesis is not excessive, apo B overproduction may cause a predominant hypercholesterolemia. 8313335 Finally, if patients with increased synthesis of apo B have both normal synthesis of TG and enhanced clearance rates of LDL, their overproduction of apo B simply may not manifest as hyperlipidemia. The patients in this study could be of this third type, and yet still be subject to accelerated atherosclerosis.
It remains to be determined whether all patients with an overproduction of apo B have a single monogenic disorder, as has been postulated for familial combined hyperlipidemia. 19 " 21 This is an important question, which extensive family and kinetic studies will be needed to resolve.
